Johnson & Johnson (NYSE:JNJ) Shares Sold by Greenfield Savings Bank

Greenfield Savings Bank cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 10,631 shares of the company’s stock after selling 113 shares during the period. Greenfield Savings Bank’s holdings in Johnson & Johnson were worth $1,537,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Cullen Investment Group LTD. boosted its stake in Johnson & Johnson by 1.8% in the fourth quarter. Cullen Investment Group LTD. now owns 69,619 shares of the company’s stock valued at $10,068,000 after acquiring an additional 1,253 shares during the period. Tealwood Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 2.9% in the 4th quarter. Tealwood Asset Management Inc. now owns 15,993 shares of the company’s stock worth $2,313,000 after purchasing an additional 458 shares during the last quarter. Grandview Asset Management LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at approximately $1,099,000. Traveka Wealth LLC increased its position in Johnson & Johnson by 216.1% in the fourth quarter. Traveka Wealth LLC now owns 6,367 shares of the company’s stock worth $921,000 after buying an additional 4,353 shares during the period. Finally, BCS Wealth Management bought a new stake in Johnson & Johnson in the fourth quarter valued at $560,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Up 0.1 %

NYSE JNJ opened at $144.68 on Wednesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a market capitalization of $348.33 billion, a P/E ratio of 20.94, a PEG ratio of 2.52 and a beta of 0.51. The company’s 50 day simple moving average is $149.12 and its 200 day simple moving average is $156.09. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.66 EPS. Equities research analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JNJ. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Morgan Stanley increased their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Bank of America reaffirmed a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Finally, Wells Fargo & Company raised their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $174.71.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.